Sample Size Efficiency of 4-Period, 2-Seq, 2-Formulation Design [RSABE / ABEL]

posted by Sereng  – USA, 2022-01-28 21:40 (107 d 21:01 ago) – Posting: # 22759
Views: 567

» Can you post a link to the guidance?

Hi Helmut, many thanks for your response. Below are the PSG links, one PSG asks you to refer to the second, although the first one may have the information (Sorry, I don't know how to attach the document here). I look forward to your guidance. Regards

https://www.accessdata.fda.gov/drugsatfda_docs/psg/Levothyroxine_Sodium%20capsules_NDA%20021924_RC%20Oct%202018.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/psg/Warfarin_Sodium_tab_09218_RC12-12.pdf


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,074 posts in 4,629 threads, 1,565 registered users;
online 7 (0 registered, 7 guests [including 7 identified bots]).
Forum time: Monday 19:41 CEST (Europe/Vienna)

Rules are for the guidance of wise men
and the blind obedience of fools.    attributed to Solon

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5